Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group
Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) dec...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2003-01-01
|
| Series: | Sarcoma |
| Online Access: | http://dx.doi.org/10.1080/1357714031000114156 |
| id |
doaj-9deb904a92f34ded865bdc876666db33 |
|---|---|
| record_format |
Article |
| spelling |
doaj-9deb904a92f34ded865bdc876666db332020-11-24T23:20:08ZengHindawi LimitedSarcoma1357-714X1369-16432003-01-017191110.1080/1357714031000114156Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology GroupJohn H. Edmonson0Louise M. Ryan1Carla I. Falkson2David G. Hicks3Ronald H. Blum4M.D., Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADana Farber Cancer Institute, Boston, MA, USAUniversity of Alabama, Birmingham, AL, USAViaHealth Rochester General Hospital, Rochester, NY, USABeth Israel Medical Center, New York, NY, USAPurpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study.http://dx.doi.org/10.1080/1357714031000114156 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
John H. Edmonson Louise M. Ryan Carla I. Falkson David G. Hicks Ronald H. Blum |
| spellingShingle |
John H. Edmonson Louise M. Ryan Carla I. Falkson David G. Hicks Ronald H. Blum Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group Sarcoma |
| author_facet |
John H. Edmonson Louise M. Ryan Carla I. Falkson David G. Hicks Ronald H. Blum |
| author_sort |
John H. Edmonson |
| title |
Phase II Study of Ifosfamide+Doxorubicin in Patients With
Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group |
| title_short |
Phase II Study of Ifosfamide+Doxorubicin in Patients With
Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group |
| title_full |
Phase II Study of Ifosfamide+Doxorubicin in Patients With
Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group |
| title_fullStr |
Phase II Study of Ifosfamide+Doxorubicin in Patients With
Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group |
| title_full_unstemmed |
Phase II Study of Ifosfamide+Doxorubicin in Patients With
Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group |
| title_sort |
phase ii study of ifosfamide+doxorubicin in patients with
advanced synovial sarcomas (e1793): a trial of the eastern cooperative oncology group |
| publisher |
Hindawi Limited |
| series |
Sarcoma |
| issn |
1357-714X 1369-1643 |
| publishDate |
2003-01-01 |
| description |
Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a
significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%)
(P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study. |
| url |
http://dx.doi.org/10.1080/1357714031000114156 |
| work_keys_str_mv |
AT johnhedmonson phaseiistudyofifosfamidedoxorubicininpatientswithadvancedsynovialsarcomase1793atrialoftheeasterncooperativeoncologygroup AT louisemryan phaseiistudyofifosfamidedoxorubicininpatientswithadvancedsynovialsarcomase1793atrialoftheeasterncooperativeoncologygroup AT carlaifalkson phaseiistudyofifosfamidedoxorubicininpatientswithadvancedsynovialsarcomase1793atrialoftheeasterncooperativeoncologygroup AT davidghicks phaseiistudyofifosfamidedoxorubicininpatientswithadvancedsynovialsarcomase1793atrialoftheeasterncooperativeoncologygroup AT ronaldhblum phaseiistudyofifosfamidedoxorubicininpatientswithadvancedsynovialsarcomase1793atrialoftheeasterncooperativeoncologygroup |
| _version_ |
1725575843661479936 |